Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil; G Fraser; B Leber; R Marks; G Quaresmini; JM Middeke; G Semenzato; W Schary; M Boyer; M Breuleux; N Crompton; K Humphrey; P Marlton

doi:10.1182/blood-2018-99-118148

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil, G Fraser, B Leber, R Marks, G Quaresmini, JM Middeke, G Semenzato, W Schary, M Boyer, M Breuleux, N Crompton, K Humphrey, P Marlton

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

5 Citations (Web of Science)

Original language	English
Journal	BLOOD
Volume	132
DOIs	https://doi.org/10.1182/blood-2018-99-118148
Publication status	Published - 2018
Event	60th Annual Meeting of the American-Society-of-Hematology (ASH) - San Diego, CA Duration: 1 Dec 2018 → 4 Dec 2018

Access to Document

10.1182/blood-2018-99-118148

Cite this

Greil, R., Fraser, G., Leber, B., Marks, R., Quaresmini, G., Middeke, JM., Semenzato, G., Schary, W., Boyer, M., Breuleux, M., Crompton, N., Humphrey, K., & Marlton, P. (2018). Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. BLOOD , 132. https://doi.org/10.1182/blood-2018-99-118148

Greil, Richard ; Fraser, G ; Leber, B et al. / Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. In: BLOOD 2018 ; Vol. 132.

@article{a96116c151c44e1ba6b62158216067ed,

title = "Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study",

author = "Richard Greil and G Fraser and B Leber and R Marks and G Quaresmini and JM Middeke and G Semenzato and W Schary and M Boyer and M Breuleux and N Crompton and K Humphrey and P Marlton",

year = "2018",

doi = "10.1182/blood-2018-99-118148",

language = "English",

volume = "132",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

note = "60th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 01-12-2018 Through 04-12-2018",

}

Greil, R, Fraser, G, Leber, B, Marks, R, Quaresmini, G, Middeke, JM, Semenzato, G, Schary, W, Boyer, M, Breuleux, M, Crompton, N, Humphrey, K & Marlton, P 2018, 'Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study', BLOOD , vol. 132. https://doi.org/10.1182/blood-2018-99-118148

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. / Greil, Richard; Fraser, G; Leber, B et al.
In: BLOOD , Vol. 132, 2018.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

AU - Greil, Richard

AU - Fraser, G

AU - Leber, B

AU - Marks, R

AU - Quaresmini, G

AU - Middeke, JM

AU - Semenzato, G

AU - Schary, W

AU - Boyer, M

AU - Breuleux, M

AU - Crompton, N

AU - Humphrey, K

AU - Marlton, P

PY - 2018

Y1 - 2018

U2 - 10.1182/blood-2018-99-118148

DO - 10.1182/blood-2018-99-118148

M3 - Abstract (Journal)

SN - 0006-4971

VL - 132

JO - BLOOD

JF - BLOOD

T2 - 60th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 1 December 2018 through 4 December 2018

ER -

Greil R, Fraser G, Leber B, Marks R, Quaresmini G, Middeke JM et al. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. BLOOD . 2018;132. doi: 10.1182/blood-2018-99-118148